Urologic panels provide focused cancer testing
Answers from the Lab
Molecular markers play an increasingly important role in managing urologic cancers. In this test-specific episode of the "Answers From the Lab" podcast, Sounak Gupta, M.B.B.S., Ph.D., explains why Mayo Clinic Laboratories' urologic NGS panels are a cost-effective way to inform prognosis and individualized treatment.
"The new test panels fill a void between single gene assays and our large solid tumor panel," Dr. Gupta says. "Within a small, targeted panel, we can address a lot of questions collectively."
Mayo Clinic urologists, oncologists, and geneticists helped determine which genes to include. "We've tried to cover the most relevant diagnostic, therapeutic and prognostic biomarkers in a disease-specific manner for kidney, bladder, and prostate cancer," Dr. Gupta says.
Some of the panels (noted below) also evaluate microsatellite instability status to help guide immunotherapy selection. "These very carefully curated panels are tools for multiple groups that help us better serve our patients," Dr. Gupta says.
Listen to learn more about Mayo Clinic Laboratories' MayoComplete urologic panels.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.